Effect of nateglinide on the incidence of diabetes and cardiovascular events

Holman, Rury R; Haffner, Steven M; McMurray, John J; Bethel, M Angelyn; Holzhauer, Björn; Hua, Tsushung A; Belenkov, Yuri; Boolell, Mitradev; Buse, John B; Buckley, Brendan M; Chacra, Antonio R; Chiang, Fu-Tien; Charbonnel, Bernard; Chow, Chun-Chung; Davies, Melanie J; Deedwania, Prakash; Diem, Peter; Einhorn, Daniel; Fonseca, Vivian; Fulcher, Gregory R; ... (2010). Effect of nateglinide on the incidence of diabetes and cardiovascular events. New England journal of medicine NEJM, 362(16), pp. 1463-76. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa1001122

Full text not available from this repository. (Request a copy)

The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition

UniBE Contributor:

Diem, Peter

ISSN:

0028-4793

Publisher:

Massachusetts Medical Society MMS

Language:

English

Submitter:

Peter Alfred von Ballmoos-Haas

Date Deposited:

04 Oct 2013 14:08

Last Modified:

16 Jul 2018 14:56

Publisher DOI:

10.1056/NEJMoa1001122

PubMed ID:

20228402

Web of Science ID:

000276894700006

URI:

https://boris.unibe.ch/id/eprint/359 (FactScience: 197704)

Actions (login required)

Edit item Edit item
Provide Feedback